Thomas Stephen Basil's Form 4 filing
Climb Bio, Inc. (CLYM) · filed Feb 17, 2026
- Accession no.
- 0001193125-26-054568
- Filed
- Feb 17, 2026
- Trade date
- Feb 12-13, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $528.8K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thomas Stephen BasilCIK 0002027962 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.2212 to $5.2481, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.6200 to $6.1200, inclusive.
Referenced by the price of 1 transaction in Table I.